LUPIN Stock Overview
Operates as a pharmaceutical company in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,036.00 |
| 52 Week High | ₹2,312.00 |
| 52 Week Low | ₹1,200.15 |
| Beta | 0.59 |
| 11 Month Change | -5.60% |
| 3 Month Change | -7.49% |
| 1 Year Change | 63.54% |
| 33 Year Change | 130.21% |
| 5 Year Change | 159.02% |
| Change since IPO | 25,176.23% |
Recent News & Updates
Recent updates
Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10
With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
Sep 17Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares
Aug 01Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jul 13Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00
Jul 12These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely
Jun 15Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results
May 09With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
May 08Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking
Apr 20Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 03Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk
Jan 19Is Lupin (NSE:LUPIN) Using Too Much Debt?
Nov 10Is Lupin (NSE:LUPIN) Using Too Much Debt?
Jun 23Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 24Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00
Jul 08Shareholder Returns
| LUPIN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.1% | 2.3% | 2.4% |
| 1Y | 63.5% | 43.8% | 29.5% |
Return vs Industry: LUPIN exceeded the Indian Pharmaceuticals industry which returned 43.8% over the past year.
Return vs Market: LUPIN exceeded the Indian Market which returned 29.5% over the past year.
Price Volatility
| LUPIN volatility | |
|---|---|
| LUPIN Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: LUPIN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LUPIN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 19,210 | Vinita Gupta | www.lupin.com |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities.
Lupin Limited Fundamentals Summary
| LUPIN fundamental statistics | |
|---|---|
| Market cap | ₹928.66b |
| Earnings (TTM) | ₹26.26b |
| Revenue (TTM) | ₹214.31b |
35.4x
P/E Ratio4.3x
P/S RatioIs LUPIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUPIN income statement (TTM) | |
|---|---|
| Revenue | ₹214.31b |
| Cost of Revenue | ₹72.03b |
| Gross Profit | ₹142.29b |
| Other Expenses | ₹116.02b |
| Earnings | ₹26.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 57.57 |
| Gross Margin | 66.39% |
| Net Profit Margin | 12.26% |
| Debt/Equity Ratio | 20.2% |
How did LUPIN perform over the long term?
See historical performance and comparison